Biosimilars | Market Events and Forecast | Endocrinology | 2025
In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3 billion. Throughout our 2023-2033 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi as well as Amgen / Daiichi Sankyo’s Prolia / Pralia will face increasing competition from biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecast for key reference brand insulins and antiresorptive analogues and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.
